An mva-based vaccine targeting the oncofetal antigen 5t4 in patients undergoing surgical resection of colorectal cancer liver metastases

Journal of Immunotherapy

Volumn 31, Issue 9, 2008, Pages 820-829

  Elkord, Eyad ^a   Dangoor, Adam ^a   Drury, Noel L ^a   Harrop, Richard ^b   Burt, Deborah J ^b   Drijfhout, Jan W ^c   Hamer, Caroline ^c   Andrews, Danielle ^d   Naylor, Stuart ^d   Sherlock, David ^e   Hawkins, Robert E ^e   Stern, Peter L ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PENNINE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

^c OXFORD BIOMEDICA UK LTD   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5T4 oncofetal antigen; Cancer vaccine; Colorectal cancer

Indexed keywords

CANCER VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ONCOFETAL ANTIGENS; TUMOR ANTIGEN;

ADENOCARCINOMA; AGED; ANTIBODY PRODUCTION; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL TUMOR; FEMALE; HUMAN; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 67650136139     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181876ab3     Document Type: Article

References (33)

1. Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis. Surg Oncol. 2007;16:33-45.
2. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23:8490-8499.
3. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev. 2006;58:931-947.
4. Mocellin S, Mandruzzato S, Bronte V, et al. Cancer vaccines: pessimism in check. Nat Med. 2004;10:1278-1279; author reply 1279-1280.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Hole N, Stern PL. A 72舁kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-246.
7. Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902.
8. Naganuma H, Kono K, Mori Y, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res. 2002;22:1033-1038.
9. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol. 1998;10:479-484.
10. Wrigley E, McGown AT, Rennison J, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5:269-274.
11. Eastham AM, Spencer H, Soncin F, et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res. 2007;67:11254-11262.
12. Spencer HL, Eastham AM, Merry CL, et al. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell. 2007;18:2838-2851.
13. Ward CM, Barrow K, Woods AM, et al. The 5T4 oncofoetal antigen is an early differentiation marker of mouse ES cells and its absence is a useful means to assess pluripotency. J Cell Sci. 2003;116:4533-4542.
14. Ward CM, Eastham AM, Stern PL. Cell surface 5T4 antigen is transiently upregulated during early human embryonic stem cell differentiation: effect of 5T4 phenotype on neural lineage formation. Exp Cell Res. 2006;312:1713-1726.
15. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4:118-132.
16. Carroll MW, Overwijk WW, Chamberlain RS, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 1997;15:387-394.
17. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 1996;93:11341-11348.
18. Harrop R, Ryan MG, Myers KA, et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother. 2006;55:1081-1090.
19. Mulryan K, Ryan MG, Myers KA, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther. 2002;1:1129-1137.
20. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12:3416-3424.
21. Elkord E, Burt DJ, Drijfhout JW, et al. CD4(+) T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25(+) T cells. Cancer Immunol Immunother. 2008;57:833-847.
22. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 2006;12:3064-3069.
23. Arlen PM, Madan RA, Hodge JW, et al. Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther. 2007;2:33-39.
24. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007;13:3776-3782.
25. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008;57:977-986.
26. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13:4487-4494.
27. Couty JP, Crain AM, Gerbaud S, et al. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine. Cancer Immunol Immunother. 2008;57:1161-1171.
28. Garbi N, Arnold B, Gordon S, et al. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004;172:5861-5869.
29. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839-849.
30. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004;5:141-149.
31. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
32. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
33. Loddenkemper C, Schernus M, Noutsias M, et al. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med. 2006;4:52.